CDA | Evidence Driven
CDA | Evidence Driven

Faslodex for Locally Advanced or Metastatic Breast Cancer – Details

Details

Files
Generic Name:
Fulvestrant
Project Status:
Complete
Therapeutic Area:
Locally advanced or metastatic breast cancer
Manufacturer:
AstraZeneca Canada Inc.
Brand Name:
Faslodex
Project Line:
Reimbursement Review
Project Number:
PC0110-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
50 mg/mL
Tumour Type:
Breast
Indications:
Locally Advanced or Metastatic Breast Cancer
Funding Request:
For hormonal treatment of non-visceral locally advanced or metastatic HER2- breast cancer in postmenopausal women, regardless of age, who have not been previously treated with endocrine therapy
Pre Noc Submission:
Yes
Sponsor:
AstraZeneca Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Fulvestrant (Faslodex) Metastatic Breast Cancer – pERC Final Recommendation Final Recommendation February 1, 2018 View PDF
Fulvestrant (Faslodex) Metastatic Breast Cancer - Final Clinical Guidance Report Guidance Reports February 1, 2018 View PDF
Fulvestrant (Faslodex) Metastatic Breast Cancer - Final Economic Guidance Report Guidance Reports February 1, 2018 View PDF
Fulvestrant (Faslodex) Metastatic Breast Cancer - pERC Initial Recommendation Initial Recommendation November 30, 2017 View PDF
Fulvestrant (Faslodex) Metastatic Breast Cancer – PAG Feedback on Initial Recommendation Feedback February 1, 2018 View PDF
Fulvestrant (Faslodex) Metastatic Breast Cancer – Manufacturer Feedback on Initial Recommendation Feedback February 1, 2018 View PDF
Fulvestrant (Faslodex) Metastatic Breast Cancer – Patient Group Feedback on Initial Recommendation Feedback February 1, 2018 View PDF
Fulvestrant (Faslodex) Metastatic Breast Cancer – Clinician Feedback on Initial Recommendation Feedback February 1, 2018 View PDF
Fulvestrant (Faslodex) Metastatic Breast Cancer – Patient Group COI Declarations COI Declarations February 1, 2018 View PDF
Fulvestrant (Faslodex) Metastatic Breast Cancer – Clinician COI Declarations COI Declarations February 1, 2018 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : February 16, 2018